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INTRODUCTION
HEME OXYGENASE (HO) is a microsomal enzyme thatplays a key role in protecting mammalian cells against
oxidative stress (12, 18, 23, 31). HO catalyzes the degrada-
tion of heme, a prooxidant, to carbon monoxide (CO),
biliverdin, and iron, by-products with antioxidant and cyto-
protective properties. There are three HO isoforms, HO-1,
HO-2, and HO-3. Expression of HO-1, a 32-kDa heat shock
protein, is induced by a variety of stimuli, including hypoxia,
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ABSTRACT
Heme oxygenase-1 (HO-1) plays a key role in protecting tissue from oxidative stress. Although some studies
implicate HO-1 in modulating thrombosis after vascular injury, the impact of HO-1 on the rate of clot forma-
tion in vivo is poorly defined. This study examined the potential function of HO-1 in regulating platelet-
dependent arterial thrombosis. Platelet-rich thrombi were induced in C57BL/6J mice by applying 10% ferric
chloride to the exposed carotid artery. Mean occlusion time of wild-type mice (n = 10) was 14.6 ± 1.0 min ver-
sus 12.9 ± 0.6 min for HO-1/ mice (n = 11, p = 0.17). However, after challenge with hemin, mean occlusion
time was significantly longer in wild-type mice (16.3 ± 1.2 min, n = 15) than HO-1/ mice (12.0 ± 1.0 min, n = 9;
p = 0.021). Hemin administration induced an approximately twofold increase in oxidative stress, measured as
plasma thiobarbituric acid reactive substances. Immunohistochemical analysis revealed that hemin induced a
robust increase in HO-1 expression within the carotid arterial wall. Ex vivo blood clotting within a collagen-
coated perfusion chamber was studied to determine whether the accelerated thrombosis observed in HO-1/
mice was contributed to by effects on the blood itself. Under basal conditions, mean clot formation during
perfusion of blood over collagen did not differ between wild-type mice and HO-1/ mice. However, after
hemin challenge, mean clot formation was significantly increased in HO-1/ mice compared with wild-type
controls. These results suggest that, under basal conditions, HO-1 does not exert a significant effect on platelet-
dependent clot formation in vivo. However, under conditions that stimulate HO-1 production, platelet-
dependent thrombus formation is inhibited by HO-1. Enhanced HO-1 expression in response to oxidative
stress may represent an adaptive response mechanism to down-regulate platelet activation under prothrom-
botic conditions. Antioxid. Redox Signal. 6, 729–735.
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shear stress, cytokines, and reactive oxygen species. HO-1 is
found in several organs, including the spleen, liver, and heart.
HO-1 also is expressed in the wall of blood vessels, where it
may play a pivotal role in the development of vascular dis-
eases, such as atherosclerosis and intimal hyperplasia, by
modulating the responses of vascular cells to oxidative stress
(9, 16, 34). Although reactive oxygen species have been im-
plicated in the pathogenesis of thrombosis (1), very little is
known regarding the potential role of HO-1 in modulating
blood clotting after vascular injury. CO produced by HO-1
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enhances the production of guanosine 3,5-cyclic mono-
phosphate (cGMP), an inhibitor of platelet activation, by
stimulating guanylyl cyclase (5). Unlike wild-type mice,
mice with complete deficiency of HO-1 develop right ven-
tricular infarctions and intracardiac thrombi in response to
hypoxia (33). In addition, suppression of HO-1 activity pro-
motes the formation of platelet-fibrin thrombi within the ar-
terioles of transplanted hearts (25). These results suggest that
HO-1 may play an important role in determining the throm-
botic response to vascular injury. However, an analysis of the
impact of HO-1 on thrombus formation after direct arterial
injury has not been reported. In addition, it is not clear
whether the observed effects of HO-1 deficiency on thrombus
formation in animal models of right ventricular infarction and
cardiac transplantation resulted from effects on the hemosta-
tic system per se, or simply from greater vascular injury in
the absence of HO-1, which led to enhanced thrombosis.
Therefore, the purpose of this study was to examine the im-
pact of HO-1 expression, in both the basal and stimulated
state, on platelet-dependent thrombosis after arterial injury.
Our results suggest that, under conditions of increased oxida-
tive stress, HO-1 plays an important antithrombotic role in
vivo, and that this effect is mediated, at least in part, by a di-
rect effect on the blood.
MATERIALS AND METHODS
Animals
The genetic background of mice used in experiments was
C57BL/6J, except for the indicated experiments that included
129/Sv mice. HO-1-deficient (HO-1/) mice, generated as
described previously (33), were back-crossed 10 genera-
tions into the C57BL/6J or the 129/Sv genetic background.
Genotyping of mice was performed by PCR analysis of tail
DNA. All experimental groups were composed of approxi-
mately 50% males/50% females. Mice were fed normal chow
(Rodent Diet 5001, LabDiet). All animal care and experimen-
tal procedures were approved by the University of Michigan
Committee on Use and Care of Animals.
Murine arterial thrombosis model
Carotid artery injury and thrombosis were induced in
16–20-week-old pentobarbital-anesthetized mice (weight
22–25 g) by placing a 1  2 mm piece of filter paper, satu-
rated with freshly prepared 10% ferric chloride (FeCl3) solu-
tion, on the adventitia of the midportion of the surgically ex-
posed carotid artery for 3 min, as described previously (35).
Blood flow was monitored with a perivascular flow probe
(Model 0.5VB, Transonic Systems). Occlusion time was de-
fined as the interval between the initiation of vascular injury
and the onset of stable occlusion, defined as loss of de-
tectable flow for 1 min. As indicated, mice received twice
daily intraperitoneal injections of hemin (15 mg/kg; Cal-
Biochem) or phosphate-buffered saline (PBS) on each of the
3 days before being subjected to carotid artery injury. The op-
erator was blinded to genotype and pharmacologic interven-
tions when performing the carotid injury protocol.
Ex vivo perfusion chamber
Clot formation during perfusion of nonanticoagulated
blood through a collagen-coated capillary tube under condi-
tions of constant flow and shear stress was performed by
modifying a previously described method (2). Mice were
anesthetized by intraperitoneal administration of sodium pen-
tobarbital (120 mg/kg) and placed on a heating pad (Fine Sci-
entific Tools). 125I-Human fibrinogen (0.5 µCi; Amersham)
was administered via tail vein injection. The inferior vena
cava was surgically exposed and cannulated with a 25-gauge
butterfly needle that was connected via silastic tubing to a
perfusion chamber consisting of two glass capillary tubes
(length of each 60 mm, 0.8 mm internal diameter, Drummond
Scientific), connected in series, the second of which was
coated with human type III collagen (Sigma), as described
(2). Tubing and capillary tubes were maintained at 37°C, and
a constant flow rate (220 µl/min) through the system was
maintained with a peristaltic pump. Blood flowed through the
perfusion chamber for 2.0 min, after which the capillary
tubes were perfused for 1 min with PBS. Before the animal
was euthanized, 50 µl of whole blood was collected. The ra-
dioactive counts per minute (cpm) emitted by the perfused,
washed collagen-coated capillary tube and by the sample of
whole blood were measured in a gamma-counter. The ratio of
(capillary tube cpm)/(blood cpm) was calculated and used as
a measure of the amount of clot formation. Control experi-
ments confirmed that clot formation within perfused capil-
lary tubes that were not coated with collagen was negligible.
In addition, induction of thrombocytopenia in mice with
busulfan, as well as pretreatment of animals with the throm-
bin inhibitor, hiurdin, markedly suppressed clot formation
during perfusion of collagen-coated capillary tubes (data not
shown). 
Immunoassays
HO-1 protein expression in situ within carotid arteries was
assessed by incubating cross-sections with polyclonal anti-
HO-1 antiserum (SPA-895, StressGen Biotechnologies), as
described previously (34). Western blot analysis of HO-1 ex-
pression in extracts prepared from carotid arteries, platelets,
and spleen was performed as described previously (20, 33).
Biochemical assays
Lipid peroxides were measured in pooled plasma as thio-
barbituric acid reactive substances (TBARS) with an assay kit
from ZeptoMetrix, according to the manufacturer’s instruc-
tions. Results were expressed as malondialdehyde (MDA)
equivalents. Platelet lysates were prepared from pooled blood
samples and processed as described previously (30). The con-
centration of cGMP within the aqueous phase of platelet
lysates was measured with a competitive enzyme immunoas-
say (Cayman), according to the manufacturer’s instructions.
Statistics
Group data are presented as means ± 1 standard error
(SEM). The Student’s t test was used to compare groups. 
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RESULTS
HO-1 inhibits thrombosis under stimulated, but not
basal conditions
The mean time required to form a thrombus that com-
pletely obstructed carotid artery blood flow was longer in
wild-type mice (14.6 ± 1.0 min, n = 10) than in HO-1/ mice
(12.9 ± 0.6 min, n = 11), although the difference between
groups was statistically insignificant (p = 0.17, Fig. 1). As
HO-1 expression is induced by a variety of stimuli (18), simi-
lar experiments were performed with mice that had received
daily injections of hemin, an inducer of oxidative stress and
HO-1 expression (23), for 3 days prior to carotid artery in-
jury. Under these conditions, thrombus formation was signif-
icantly faster in HO-1-deficient mice compared with wild-
type controls, with a mean occlusion time of 16.3 ± 1.2 min
for wild-type mice (n = 15) versus 12.0 ± 1.0 min for 
HO-1/ mice (n = 9, p = 0.02).
In addition to inducing HO-1 expression, hemin is an HO-1
substrate (32). If hemin itself were prothrombotic, it is possi-
ble that thrombosis after hemin administration might be
faster in HO-1-deficient mice than in wild-type mice due to a
reduced capacity of the former group to metabolize hemin. To
examine this possibility, a piece of filter paper saturated with
hemin (40 mg/ml) was applied to the surface of the carotid
artery for 3 min (n = 1 mouse) or for 10 min (n = 3 mice), and
carotid blood flow was monitored. No evidence of thrombosis
was observed in any of the mice during 30 min of flow moni-
toring. Thereafter, FeCl3-saturated filter paper was applied to
the same carotid artery previously exposed to hemin. Mean
time to formation of an occlusive thrombus was 17.8 ± 4.8
min (n = 4), results similar to those of wild-type mice not ex-
posed to hemin (16.3 ± 1.2 min). These results, and the fact
that 3 days of hemin administration did not accelerate throm-
bus formation in wild-type mice (Fig. 1), suggested that
hemin itself did not promote platelet-dependent carotid artery
thrombosis.
Hemin induces oxidative stress 
and vascular expression of HO-1
To confirm that hemin administration induced oxidative
stress, hemin was administered to wild-type mice (n = 6;
4 were C57BL/6J, 2 were 129/Sv) for 3 days in the same man-
ner as for the thrombosis experiments. Control mice (n = 6; 4
were C57BL/6J, 2 were 129/Sv) received identical injections of
PBS. TBARS were twofold higher in pooled plasma prepared
from hemin-treated mice (0.72 nmol/ml MDA) compared with
pooled plasma prepared from control mice (0.35 nmol/ml
MDA). Carotid arteries, platelets, and spleens were retrieved
from mice at the time of blood collection. We were unable to
detect HO-1 protein in platelet or carotid artery extracts of
wild-type mice by western blotting, including after hemin ex-
posure, although HO-1 was readily detected in spleen, where
its expression was up-regulated by hemin (data not shown).
However, by using the more sensitive method of immunohisto-
chemistry, we were able to demonstrate that arterial wall ex-
pression of HO-1 was clearly increased by hemin administra-
tion, particularly within the media (Fig. 2).
We attempted to identify potential mechanisms underlying
the effect of HO-1 on thrombus formation. CO, a by-product
of HO-1 metabolism of heme, stimulates production of
cGMP, an inhibitor of platelet aggregation (5). We measured
platelet cGMP levels in wild-type mice and HO-1/ mice
that were treated with hemin or with vehicle control for
3 days to test the hypothesis that cGMP production would be
reduced in platelets from HO-1/ mice. Platelet cGMP was
1.8–2.0-fold higher in wild-type mice treated with hemin ver-
sus vehicle (Table 1). However, basal platelet cGMP levels
were similar in HO-1/ mice compared with wild-type mice,
and the increase in platelet cGMP concentration induced by
hemin in HO-1/ mice (1.6-fold) did not appear to be signif-
icantly blunted compared with that observed in wild-type
mice. Biliverdin also is produced by HO-1 during heme
degradation and is immediately converted to bilirubin (8). To
examine its potential effects on thrombosis, biliverdin
(5 mg/kg; Sigma) was administered to mice by tail vein injec-
tion, whereas control mice received an equal volume of vehi-
cle. Fifteen minutes later, FeCl3 was applied to arteries and
thrombosis times were measured. The mean occlusion time of
biliverdin-treated mice (9.2 ± 0.72 min, n = 5) was not signif-
icantly different from that of control mice (9.8 ± 1.5 min,
n = 5), suggesting that biliverdin did not mediate the effect of
HO-1 genotype on thrombosis in our model system.
Induction of HO-1 expression decreases clot
formation in an ex vivo perfusion chamber
Accelerated thrombosis in the absence of HO-1 could re-
sult from effects on the blood and/or the blood vessel wall. To
determine if HO-1 modulates the thromboreactivity of blood,
we used a collagen-coated ex vivo perfusion chamber to study
clot formation under pathophysiologically relevant condi-
tions, but in the absence of a blood vessel wall. Mean clot for-
mation during 2 min of blood flow through the perfusion
chamber in wild-type mice (0.11 ± 0.003, n = 14, Fig. 3) did
not differ significantly from that observed in HO-1/ mice
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FIG. 1. Mean occlusion times after initiation of vascular
injury in wild-type (WT) mice and HO-1/ mice. Under
basal (unstimulated) conditions, there was no significant dif-
ference between groups. After 3 days of hemin exposure, mean
occlusion time of wild-type mice was significantly longer than
that of HO-1/ mice. *p = 0.02 versus hemin-treated wild-
type mice.
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(0.12 ± 0.006, n = 14, p = 0.11). However, after 3 days of
hemin challenge, mean clot formation was significantly less
in wild-type mice (0.049 ± 0.09, n = 6) than HO-1/ mice
(0.099 ± 0.012, n = 6, p < 0.01). Therefore, under conditions
of increased oxidative stress, ex vivo clot formation was ac-
celerated in HO-1/ mice compared with wild-type mice.
These results suggested that HO-1 modulates thrombosis, at
least in part, by affecting the blood itself.
DISCUSSION
In this study, we examined the role of HO-1 in regulating
intravascular clot formation, an early and critical response of
arteries to stress. We demonstrated that, under conditions of
increased oxidative stress, mice with complete HO-1 defi-
ciency exhibit an accelerated thrombotic response to vascular
injury compared with wild-type mice. Our results identify
HO-1 as an important inhibitor of thrombus growth in vivo.
Previous studies addressing the vascular biology of HO-1 fo-
cused predominantly on its function in modulating processes
such as vasoreactivity, vascular smooth muscle cell prolifera-
tion, and atherosclerosis (9, 16, 26, 34). As thrombi contain
vasoactive compounds and mitogens, such as thromboxane A2
and platelet-derived growth factor, it is possible that the ca-
pacity of HO-1 to protect against vasoconstriction, neointima
formation, and atherosclerosis development may be mediated
to some extent by its antithrombotic properties.
Previous studies demonstrated that HO-1 protects against
the development of intracardiac thrombi during hypoxia and
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FIG. 2. Induction of arterial HO-1 expression by hemin. (A) Hemin or PBS (control) was administered to C57BL/6J wild-
type mice for 3 days. Carotid arteries (which were not injured by FeCl3) were retrieved, and HO-1 expression was studied by im-
munohistochemistry. Arterial cross-sections prepared from three control mice (upper row) and from three hemin-treated mice
(lower row) are shown. (B) Immunohistochemical analysis of spleen tissue from a wild-type (WT) mouse and an HO-1/ mouse,
demonstrating specificity of the anti-HO-1 antibody.
TABLE 1. EFFECT OF HEMIN ADMINISTRATION ON PLATELET CGMP LEVELS
Genetic background Platelet cGMP Ratio of platelet cGMP in
genotype Treatment (pmol/109 platelets) hemin- vs. PBS-treated mice
C57BL6J, wild-type PBS (n = 4) 0.076 2.0
Hemin (n = 4) 0.148
129/Sv, wild-type PBS (n = 2) 0.026 1.8
Hemin (n = 2) 0.047
129/Sv, HO-1/ PBS (n = 2) 0.035 1.6
Hemin (n = 2) 0.057
All cGMP measurements were made from pooled platelet samples prepared from the number of
mice indicated in column 2.
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arteriolar thrombi after cardiac transplantation (25, 33). How-
ever, it was not possible to determine from these studies if al-
teration of HO-1 expression affected the reactivity of blood
itself to thrombotic stimuli, because increased thrombosis
could have been driven by an increase in tissue injury that re-
sulted from suppression of HO-1 function. Our ex vivo per-
fusion chamber studies demonstrate that HO-1, when up-
regulated by oxidative stress, can alter the clotting tendency
of flowing blood, because vascular wall cell injury was not a
component of this experimental system. Earlier studies dem-
onstrated that transient exposure of isolated platelets to cul-
tured endothelial or vascular smooth muscle cells inhibited in
vitro platelet aggregation in an HO-1-dependent manner (25,
29). The thrombi that form in response to FeCl3 arterial injury
are platelet-rich (10), and platelet activation drives clot for-
mation during perfusion of blood over a collagen-coated sur-
face. Therefore, our studies suggest that HO-1 functions in
vivo to suppress platelet activation, at least under conditions
that up-regulate HO-1 expression. However, it is also possible
that the enhanced thrombotic response observed in our ca-
rotid artery experiments could have been contributed to by
enhanced vascular wall cell necrosis after FeCl3 injury.
We used hemin in our experiments to induce HO-1 expres-
sion, a method used by several other investigators (6, 19, 27).
The mechanism by which hemin induces HO-1 is not pre-
cisely defined. However, hemin is recognized to induce ox-
idative stress, a key trigger of HO-1 expression, and we dem-
onstrated that plasma TBARS increased in mice after hemin
administration. Hemin catalyzes lipid peroxidation within
cell membranes (28). This effect may be mediated by release
of iron from hemin, catalyzed either by HOs or by peroxides
(3, 13, 17, 36). Free iron can contribute to the production of
hydroxyl radicals via the Fenton reaction (15). Hemin may
also directly catalyze lipid peroxidation by reacting with
membrane lipid peroxides (21).
Although the main goal of our study was to determine if
HO-1 can modulate clot formation in vivo, we also attempted
to identify potential mechanisms underlying HO-1’s an-
tithrombotic effect. We demonstrated that HO-1 protein is in-
creased within the vascular wall after hemin exposure, sug-
gesting that arteries can respond to oxidative stress, a poten-
tial trigger of thrombosis (1), by up-regulating HO-1 expres-
sion. Increased vascular HO-1 expression could lead to en-
hanced release of CO into the circulation, where it could
inhibit platelet function by stimulating the production of
cGMP by guanylyl cyclase (5, 25, 29, 31). By this hypothesis,
one would anticipate decreased platelet cGMP levels in 
HO-1/ mice compared with wild-type mice. However, we
failed to observe such a difference, although the number of
mice in our experimental groups was very small, and these
data must be interpreted with caution. Future experiments, in
which thrombosis is studied in mice after exposure to exoge-
nous CO or to a guanylyl cyclase inhibitor, should help to de-
fine better the in vivo significance of cGMP as a downstream
mediator of HO-1’s effect on thrombosis. Biliverdin, another
product of heme degradation by HO-1, is rapidly converted to
bilirubin, which has antioxidative properties that potentially
could affect thrombus formation (8). Our experiment involv-
ing biliverdin administration did not support a key role for
biliverdin/bilirubin production in modulating the antithrom-
botic effects of HO-1 in our model system. However, further
experiments are necessary to define better the potential effects
of biliverdin production on thrombosis. Effects of HO-1 ex-
pression on iron metabolism must also be considered as a po-
tential mechanism underlying our in vivo data. It is possible
that abnormal accumulation of iron within cells, as has been
observed in HO-1 deficiency (22), could have contributed to
increased vascular injury or enhanced platelet reactivity in our
studies (4, 24). In a previous study, we demonstrated that
chronic iron administration increases vascular oxidative stress
and accelerates thrombus formation after murine arterial in-
jury (7). Effects of HO-1 deficiency on the expression of other
heme oxygenases could potentially affect thrombus formation
after vascular injury. However, previous studies suggest that
HO-2 expression is not significantly altered in HO-1/ mice
(33). Although our studies suggest that HO-1 suppresses clot
formation by inhibiting platelet function in vivo, they do not
definitively establish this as the mechanism underlying 
HO-1’s effect. Other mechanisms are possible, including CO-
dependent suppression of plasminogen activator inhibitor-1
expression (11), and potential effects of HO-1 on tissue factor
expression (14). Further studies are necessary to identify the
mechanisms by which HO-1 modulates thrombus formation
after vascular injury. It also will be important to examine the
effect on thrombosis of other stimuli of HO-1 expression with
more physiologic and pathophysiologic relevance than hemin,
such as hypoxia and lipopolysaccharide.
In summary, we have demonstrated that, under basal condi-
tions, HO-1 does not exert a significant effect on platelet-
dependent clot formation in vivo. However, in response to ox-
idative stress, platelet-dependent thrombus formation is
inhibited by HO-1. This effect is mediated, at least in part, by
a reduction in the responsiveness of flowing blood to throm-
botic stimuli. Our studies suggest that strategies aimed at en-
hancing HO-1 expression may be of therapeutic potential in
the management and prevention of thrombotic diseases. Fur-
thermore, they suggest that an increase in HO-1 expression in
response to oxidative stress may represent an adaptive re-
sponse mechanism to down-regulate clot formation under
prothrombotic conditions.
HEME OXYGENASE-1 AND THROMBOSIS 733
FIG. 3. Ex vivo clot formation in wild-type versus HO-1/
mice. Blood was routed from the inferior vena cava through a
collagen-coated capillary tube, and ex vivo clot formation was
measured. Mice were studied under basal (i.e., unstimulated)
conditions or after receiving hemin for 3 days. *p < 0.01 versus
hemin-treated HO-1/ mice.
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